Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.44 |
| ▸ | FAP | Q12884 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21649698 | 1.00 | FURIN (0.44) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL24520454 | 0.94 | FAP (0.47) | FURINFAPHTTMAP1LC3BNPY1R | |
| SCHEMBL9943152 | 0.94 | FAP (0.47) | FURINFAPHTTMAP1LC3BNPY1R | |
| SCHEMBL18244335 | 0.93 | FAP (0.40) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL18244334 | 0.93 | FAP (0.40) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL22746548 | 0.93 | FAP (0.42) | FURINFAPMAP1LC3BNPY1RNPY2R | |
| SCHEMBL24028236 | 0.93 | FAP (0.42) | FURINFAPMAP1LC3BNPY1RNPY2R | |
| SCHEMBL21883412 | 0.92 | FURIN (0.42) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL24916473 | 0.92 | FURIN (0.42) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL22336599 | 0.91 | FAP (0.40) | FURINFAPHTTPDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177578-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210283267-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | VOR BIOPHARMA, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228696-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | CD40LG, CD44, CD74 | FURIN 3901/4885FAP 3392/4885HTT 439/4885 |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | FURIN 2941/4885FAP 1883/4885HTT 1343/4885 |
| US-20210283267-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | CD44, FCGR1A, FCGR3B | FURIN 4036/4885FAP 3637/4885HTT 375/4885 |
| US-20210371524-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD44, LY6K, CD2 | FURIN 4629/4885FAP 1273/4885HTT 505/4885 |
| US-20220177578-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | MYADM, SIGLEC7, ITGB7 | FURIN 3138/4885FAP 1354/4885HTT 2662/4885 |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | FURIN 2941/4885FAP 1883/4885HTT 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.